<DOC>
	<DOC>NCT02999295</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and efficacy of the combination therapy of ramucirumab and nivolumab in participants with advanced or recurrent unresectable gastric or GEJ cancer.</brief_summary>
	<brief_title>A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Advanced or recurrent unresectable gastric or GEJ cancer Histologically confirmed adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma or poorly differentiated adenocarcinoma), signetring cell carcinoma, mucinous adenocarcinoma or hepatoid adnocarcinoma Patients with normal oral intake Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Patients who have measurable target lesion Patients has a refractory or intolerant pretreatment by pyrimidine fluoride anticancer agent and platinumbased anticancer agent Patients with adequate organ function Patients with no pretreatment history including ramucirumab, nivolumab or other therapies targeting control of T cells Patients with written informed consent Patients have double cancer Patients have infection required systemic therapy Known central vervous system (CNS) metastasis Patients with history of pneumonitis or pulmonary fibrosis Patients with history of serious anaphylaxis induced by antibody preparation Patients who have known active autoimmune disease or history of chronic recurrent autoimmune disease Female who is pregnant, lactating or suspected pregnancy Patients with psychosis or dementia to interfere to obtain informed consent appropriately</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>